Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Spectroscopic and structural investigations on modafinil by FT-IR, FT-Raman, NMR, UV-Vis and DFT methods.

Selvaraj S, Rajkumar P, Kesavan M, Thirunavukkarasu K, Gunasekaran S, Devi NS, Kumaresan S.

Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 5;224:117449. doi: 10.1016/j.saa.2019.117449. Epub 2019 Aug 4.

PMID:
31422339
2.

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.

Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, Thirunavukkarasu K.

RMD Open. 2019 Feb 23;5(1):e000742. doi: 10.1136/rmdopen-2018-000742. eCollection 2019.

3.

Optimum Response Filter Setting for Air Conduction-Induced Ocular Vestibular Evoked Myogenic Potential.

Singh NK, Thirunavukkarasu K, Barman A.

J Am Acad Audiol. 2019 Oct;30(9):753-763. doi: 10.3766/jaaa.17098. Epub 2018 Nov 15.

PMID:
30430985
4.

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.

Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K.

Rheumatol Ther. 2018 Dec;5(2):383-401. doi: 10.1007/s40744-018-0118-2. Epub 2018 Jun 11.

5.

Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.

Bird P, Bensen W, El-Zorkany B, Kaine J, Manapat-Reyes BH, Pascual-Ramos V, Witcombe D, Soma K, Zhang R, Thirunavukkarasu K.

J Clin Rheumatol. 2019 Apr;25(3):115-126. doi: 10.1097/RHU.0000000000000786. Review.

6.

A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.

Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.

J Med Chem. 2017 Jul 13;60(13):5933-5939. doi: 10.1021/acs.jmedchem.7b00650. Epub 2017 Jun 29.

PMID:
28613895
7.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.

Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

8.

Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Jones SB, Pfeifer LA, Bleisch TJ, Beauchamp TJ, Durbin JD, Klimkowski VJ, Hughes NE, Rito CJ, Dao Y, Gruber JM, Bui H, Chambers MG, Chandrasekhar S, Lin C, McCann DJ, Mudra DR, Oskins JL, Swearingen CA, Thirunavukkarasu K, Norman BH.

ACS Med Chem Lett. 2016 Aug 2;7(9):857-61. doi: 10.1021/acsmedchemlett.6b00207. eCollection 2016 Sep 8.

9.

Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.

Thirunavukkarasu K, Swearingen CA, Oskins JL, Lin C, Bui HH, Jones SB, Pfeifer LA, Norman BH, Mitchell PG, Chambers MG.

Osteoarthritis Cartilage. 2017 Jun;25(6):935-942. doi: 10.1016/j.joca.2016.09.006. Epub 2016 Sep 13.

10.

Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.

Thirunavukkarasu K, Tan B, Swearingen CA, Rocha G, Bui HH, McCann DJ, Jones SB, Norman BH, Pfeifer LA, Saha JK.

J Pharmacol Exp Ther. 2016 Oct;359(1):207-14. doi: 10.1124/jpet.116.234013. Epub 2016 Aug 11.

PMID:
27516465
11.

Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.

Wiley MR, Durham TB, Adams LA, Chambers MG, Lin C, Liu C, Marimuthu J, Mitchell PG, Mudra DR, Swearingen CA, Toth JL, Weller JM, Thirunavukkarasu K.

J Med Chem. 2016 Jun 23;59(12):5810-22. doi: 10.1021/acs.jmedchem.6b00398. Epub 2016 Jun 9.

PMID:
27194201
12.

One-year prevalence and risk factors of tinnitus in children with otological problems.

Thirunavukkarasu K, Geetha C.

Int Tinnitus J. 2015;19(2):33-8. doi: 10.5935/0946-5448.20150006.

PMID:
27186930
13.

Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice.

Spelman L, Su JC, Fernandez-Peñas P, Varigos GA, Cooper AJ, Baker CS, Lee M, Ring JM, Thirunavukkarasu K.

J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2184-91. doi: 10.1111/jdv.13210. Epub 2015 Sep 14.

PMID:
26370225
14.
15.

Intraarticular Matrix Metalloproteinases and Aggrecan Degradation Are Elevated After Articular Fracture.

Haller JM, Swearingen CA, Partridge D, McFadden M, Thirunavukkarasu K, Higgins TF.

Clin Orthop Relat Res. 2015 Oct;473(10):3280-8. doi: 10.1007/s11999-015-4441-4. Epub 2015 Jul 11.

16.

Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.

Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.

J Med Chem. 2014 Dec 26;57(24):10476-85. doi: 10.1021/jm501522n. Epub 2014 Dec 5.

PMID:
25415648
17.

Selective Autooxidation of Ethanol over Titania-Supported Molybdenum Oxide Catalysts: Structure and Reactivity.

Caro C, Thirunavukkarasu K, Anilkumar M, Shiju NR, Rothenberg G.

Adv Synth Catal. 2012 May 7;354(7):1327-1336. Epub 2012 Apr 19.

18.

One-year prevalence and risk factors of tinnitus in older individuals with otological problems.

Thirunavukkarasu K, Geetha C.

Int Tinnitus J. 2013;18(2):175-81. doi: 10.5935/0946-5448.20130023.

PMID:
25773112
19.

Characterization of an Autographa californica multiple nucleopolyhedrovirus dual mutant: ORF82 is required for budded virus production, and a point mutation in LEF-8 alters late and abolishes very late transcription.

Gauthier D, Thirunavukkarasu K, Faris BL, Russell DL, Weaver RF.

J Gen Virol. 2012 Feb;93(Pt 2):364-73. doi: 10.1099/vir.0.037028-0. Epub 2011 Oct 26.

PMID:
22031528
20.

Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.

Standfield L, Norris S, Harvey C, Elliot L, Riordan J, Hall S, Day R, Nash P, Thirunavukkarasu K, Robertson J, Palmer T.

Clin Ther. 2010 Jul;32(7):1329-42. doi: 10.1016/j.clinthera.2010.07.006.

PMID:
20678681
21.

Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine.

Swearingen CA, Carpenter JW, Siegel R, Brittain IJ, Dotzlaf J, Durham TB, Toth JL, Laska DA, Marimuthu J, Liu C, Brown DP, Carter QL, Wiley MR, Duffin KL, Mitchell PG, Thirunavukkarasu K.

Osteoarthritis Cartilage. 2010 Sep;18(9):1150-8. doi: 10.1016/j.joca.2010.06.011. Epub 2010 Jul 13.

22.

A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs.

Swearingen CA, Chambers MG, Lin C, Marimuthu J, Rito CJ, Carter QL, Dotzlaf J, Liu C, Chandrasekhar S, Duffin KL, Mitchell PG, Durham TB, Wiley MR, Thirunavukkarasu K.

Osteoarthritis Cartilage. 2010 Sep;18(9):1159-66. doi: 10.1016/j.joca.2010.02.019. Epub 2010 Jul 13.

23.

Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence.

Foley PA, Quirk C, Sullivan JR, Dolianitis C, Hack SP, Thirunavukkarasu K, Cooper AJ.

J Eur Acad Dermatol Venereol. 2010 Oct;24(10):1135-43. doi: 10.1111/j.1468-3083.2010.03613.x. Review.

PMID:
20337816
24.

Kinetic evidence for the influence of subsurface oxygen on palladium surfaces towards CO oxidation at high temperatures.

Gopinath CS, Thirunavukkarasu K, Nagarajan S.

Chem Asian J. 2009 Jan 5;4(1):74-80. doi: 10.1002/asia.200800278.

PMID:
18844311
25.

Development and characterization of a novel ELISA based assay for the quantitation of sub-nanomolar levels of neoepitope exposed NITEGE-containing aggrecan fragments.

Carter QL, Dotzlaf J, Swearingen C, Brittain I, Chambers M, Duffin K, Mitchell P, Thirunavukkarasu K.

J Immunol Methods. 2007 Dec 1;328(1-2):162-8. Epub 2007 Oct 1.

PMID:
17942111
26.

Characterization of the human ADAMTS-5 (aggrecanase-2) gene promoter.

Thirunavukkarasu K, Pei Y, Wei T.

Mol Biol Rep. 2007 Dec;34(4):225-31. Epub 2007 Jan 9.

PMID:
17211519
27.

Regulation of NFATc2 gene expression by the transcription factor Runx2.

Thirunavukkarasu K, Pei Y, Moore TL, Wei T, Wang H, Chandrasekhar S.

Mol Biol Rep. 2007 Mar;34(1):1-10. Epub 2006 Nov 11.

PMID:
17103021
28.

Isothermal kinetic study of nitric oxide adsorption and decomposition on Pd(111) surfaces: molecular beam experiments.

Thirunavukkarasu K, Thirumoorthy K, Libuda J, Gopinath CS.

J Phys Chem B. 2005 Jul 14;109(27):13283-90.

PMID:
16852656
29.

A molecular beam study of the NO + CO reaction on Pd(111) surfaces.

Thirunavukkarasu K, Thirumoorthy K, Libuda J, Gopinath CS.

J Phys Chem B. 2005 Jul 14;109(27):13272-82.

PMID:
16852655
30.

Regulation of the human ADAMTS-4 promoter by transcription factors and cytokines.

Thirunavukkarasu K, Pei Y, Moore TL, Wang H, Yu XP, Geiser AG, Chandrasekhar S.

Biochem Biophys Res Commun. 2006 Jun 23;345(1):197-204. Epub 2006 May 4.

PMID:
16677612
31.

Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects.

Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K.

Osteoarthritis Cartilage. 2006 Aug;14(8):749-58. Epub 2006 Mar 20.

32.

Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.

Onyia JE, Galvin RJ, Ma YL, Halladay DL, Miles RR, Yang X, Fuson T, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, Bryant HU, Martin TJ.

J Pharmacol Exp Ther. 2004 Apr;309(1):369-79. Epub 2004 Jan 12.

PMID:
14718597
33.

Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells.

Thirunavukkarasu K, Halladay DL, Miles RR, Geringer CD, Onyia JE.

J Cell Biochem. 2002;85(4):837-50.

PMID:
11968023
34.

Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression.

Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE.

J Cell Biochem. 2001;84(1):1-11.

PMID:
11746511
35.

Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.

Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE.

J Biol Chem. 2001 Sep 28;276(39):36241-50. Epub 2001 Jul 12.

36.

ADAMTS-1: A cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone.

Miles RR, Sluka JP, Halladay DL, Santerre RF, Hale LV, Bloem L, Thirunavukkarasu K, Galvin RJ, Hock JM, Onyia JE.

Endocrinology. 2000 Dec;141(12):4533-42.

PMID:
11108265
37.

The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function.

Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE.

J Biol Chem. 2000 Aug 18;275(33):25163-72.

38.

Cryptic enhancer elements in luciferase reporter vectors respond to the osteoblast-specific transcription factor Osf2/Cbfa1.

Thirunavukkarasu K, Miles RR, Halladay DL, Onyia JE.

Biotechniques. 2000 Mar;28(3):506-10.

39.

The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1.

McLarren KW, Lo R, Grbavec D, Thirunavukkarasu K, Karsenty G, Stifani S.

J Biol Chem. 2000 Jan 7;275(1):530-8.

40.

Dynamic regulation of RGS2 in bone: potential new insights into parathyroid hormone signaling mechanisms.

Miles RR, Sluka JP, Santerre RF, Hale LV, Bloem L, Boguslawski G, Thirunavukkarasu K, Hock JM, Onyia JE.

Endocrinology. 2000 Jan;141(1):28-36.

PMID:
10614620
41.

CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia.

Zhou G, Chen Y, Zhou L, Thirunavukkarasu K, Hecht J, Chitayat D, Gelb BD, Pirinen S, Berry SA, Greenberg CR, Karsenty G, Lee B.

Hum Mol Genet. 1999 Nov;8(12):2311-6.

PMID:
10545612
42.

Disseminated nocardiosis in a bone marrow transplant recipient with chronic GVHD.

Bhave AA, Thirunavukkarasu K, Gottlieb DJ, Bradstock K.

Bone Marrow Transplant. 1999 Mar;23(5):519-21.

43.
44.

Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia.

Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G.

Nat Genet. 1997 Jul;16(3):307-10.

PMID:
9207800
46.

Pyocele after appendicectomy.

Umapathy A, Thirunavukkarasu KN.

J Indian Med Assoc. 1985 Jan;83(1):27. No abstract available.

PMID:
4008954
47.

Treatment of alcoholic lactic acidosis.

Thirunavukkarasu K.

Med J Aust. 1979 Dec 1;2(11):583-4.

PMID:
530172
48.

Soluble insulin in the tropics.

Thirunavukkarasu K.

Ceylon Med J. 1968 Sep;13(3):150-3. No abstract available.

PMID:
5721560
49.

Leptospirosis in Ceylonese children.

Thirunavukkarasu K, De Silva VN, Amarasinghe G.

Ceylon Med J. 1967 Dec;12(4):202-5. No abstract available.

PMID:
5599940
50.

Coagulation of rubber latex in the stomach.

Thirunavukkarasu K, Yoheswaran K.

Br Med J. 1967 Nov 25;4(5577):484. No abstract available.

Supplemental Content

Loading ...
Support Center